Medtronic Expand URO trial meets Hugo RAS safety and effectiveness endpoints
Medtronic announced that its Expand URO U.S. clinical trial for the Hugo RAS system met primary safety and effectiveness endpoints.
Evidence notes
- The study evaluated Hugo RAS for urologic surgical procedures in the United States.
- Medtronic said the results supported its submission pathway for Hugo RAS in urology.
Company context
Medtronic is a global medical technology company with surgical robotics exposure through the Hugo robotic-assisted surgery system.